Close Menu

Infectious Disease

News on research and diagnostic development for pathogenic diseases.

Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.

The firm said that its new hematology-based cellular biomarker test has the potential to advance clinicians’ approach to sepsis triage and diagnosis.

Decreased sales in the firm's centralized and point-of-care business and diabetes care business were partially offset by strong growth in the molecular diagnostics business.

The Austin, Texas-based company offers more than 30 tests, including those for food sensitivity, fertility and women's hormones, sexually transmitted diseases, and thyroid.

The two organizations will seek to engage stakeholders worldwide in order to increase demand for and access to HCV diagnostics.